Angiotensin II
Research News and Information

Sunday, November 22, 2009

Metoprolol reduces cerebral tissue oxygen tension after acute hemodilution in rats.

30 Oct 2009 BACKGROUND: Perioperative beta-blockade and anemia are independent predictors of increased stroke and mortality by undefined mechanisms. This study investigated the effect of beta-blockade on cerebral tissue oxygen delivery in an experimental model ... Read more...

Genetic silencing of Nox2 and Nox4 reveals differential roles of these NADPH oxidase homologues in the vasopressor and dipsogenic effects of brain angiotensin II.

3 Oct 2009 The renin-angiotensin system exerts a tremendous influence over fluid balance and arterial pressure. Angiotensin II (Ang-II), the effector peptide of the renin-angiotensin system, acts in the central nervous system to regulate neurohumoral outflow ... Read more...

Interaction between renin-angiotensin and sympathetic nervous systems in a rat model of pressure overload cardiac hypertrophy.

29 Sep 2009 1 A raised cardiac workload activates neurohormones which will increase muscle mass and shift contractility to the right along the Frank-Starling curve. 2 This study examined the interaction between the SNS and RAS in contributing to vascular ... Read more...

Latest indexed articles for 'Angiotensin II'

These are the very latest articles for this heading:

• Metoprolol reduces cerebral tissue oxygen tension after acute hemodilution in rats. 30 Oct 2009
• Matrix metalloproteinase-8 and the regulation of blood pressure, vascular inflammation, and atherosclerotic lesion growth. 21 Oct 2009
• Genetic silencing of Nox2 and Nox4 reveals differential roles of these NADPH oxidase homologues in the vasopressor and dipsogenic effects of brain angiotensin II. 3 Oct 2009
• Interaction between renin-angiotensin and sympathetic nervous systems in a rat model of pressure overload cardiac hypertrophy. 29 Sep 2009
• PYK2/PDZ-RhoGEF links Ca2+ signaling to RhoA. 29 Sep 2009
• Angiotensin II effects on ischemic focal ventricular tachycardia are predominantly mediated through myocardial AT(2) receptor. 23 Sep 2009
• Additive beneficial effects of lactotripeptides and aerobic exercise on arterial compliance in postmenopausal women. 23 Sep 2009
• The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues. 22 Sep 2009
• Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. 15 Sep 2009
• Transcriptional upregulation of mitochondrial uncoupling protein 2 protects against oxidative stress-associated neurogenic hypertension. 15 Sep 2009
• Shear stress regulates angiotensin type 1 receptor expression in endothelial cells. 15 Sep 2009
• Differential effects of mechanical and biological stimuli on matrix metalloproteinase promoter activation in the thoracic aorta. 13 Sep 2009
• Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. 12 Sep 2009
• High ambient glucose induces angiotensin-independent AT-1 receptor activation, leading to increases in proliferation and extracellular matrix accumulation in MES-13 mesangial cells. 12 Sep 2009
• Vasopressin is a major vasoconstrictor involved in hindlimb vascular responses to stimulation of adenosine A(1) receptors in the nucleus of the solitary tract. 9 Sep 2009
• Angiotensin II enhances GABA(B) receptor-mediated responses and expression in nucleus tractus solitarii of rats. 9 Sep 2009
• A role of matrix metalloproteinase-8 in atherosclerosis. 8 Sep 2009
• Understanding abdominal aortic aneurysm. 8 Sep 2009
• Angiotensin II type-1 receptor regulates RhoA and Rho-kinase/ROCK activation via multiple mechanisms. Focus on "Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells". 7 Sep 2009
• Docosahexaenoic acid down-regulates endothelial Nox 4 through a sPLA2 signalling pathway. 4 Sep 2009

See a longer list of these articles.

Technical information about 'Angiotensin II'

Definition: An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.

Chemical name: Angiotensin II

Registry Number: 11128-99-7

Descriptor UI: D000804

Alternative terms: Angiotensin II; Angiotensin-(1-8) Octapeptide; ANG-(1-8)Octapeptide; Angiotensin II, Val(5)-; Valyl(5)-Angiotensin II; Angiotensin II, Valine(5)-; Angiotensin II, Ile(5)-; Isoleucyl(5)-Angiotensin II; Isoleucine(5)-Angiotensin; 5-L-Isoleucine Angiotensin II; 5 L Isoleucine Angiotensin II; Angiotensin II, 5-L-Isoleucine; II, 5-L-Isoleucine Angiotensin; Angiotensin II, Isoleucine(5)-;

Related Mesh Headings: Renin-Angiotensin System;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Vasoconstrictor Agents;

Tree Number: D06.472.699.094.078; D12.644.400.070.078; D12.644.456.073.041; D12.644.548.058.078; D12.776.641.650.070.078; D23.469.050.050.050;

History Note: 1974(1963); for ANGIOTENSIN II, ILE(5)- use ANGIOTENSIN II (NM) 1974-1999